CHRS vs. ET

Last updated Jun 3, 2026

CHRS (Coherus BioSciences, Inc.) and ET (Energy Transfer LP) are both stocks. CHRS operates in Biotechnology (Healthcare), while ET operates in Oil & Gas Midstream (Energy). Over the past 10 years, CHRS returned -22.02%/yr vs 12.65%/yr for ET. At a 0.19 correlation, their price movements are largely independent.

Performance

CHRS vs. ET - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and Energy Transfer LP (ET). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CHRS achieves a 7.04% return, which is significantly lower than ET's 22.80% return. Over the past 10 years, CHRS has underperformed ET with an annualized return of -22.02%, while ET has yielded a comparatively higher 12.65% annualized return.

CHRS

• 1D: -3.18%
• 1M: -15.56%
• YTD: 7.04%
• 6M: 31.03%
• 1Y: 98.43%
• 3Y*: -30.10%
• 5Y*: -34.94%
• 10Y*: -22.02%

ET

• 1D: 1.40%
• 1M: -0.32%
• YTD: 22.80%
• 6M: 22.06%
• 1Y: 20.43%
• 3Y*: 24.37%
• 5Y*: 22.55%
• 10Y*: 12.65%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CHRS vs. ET - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CHRS Coherus BioSciences, Inc.	7.04%	2.90%	-58.56%	-57.95%	-50.38%	-8.17%	-3.47%	98.95%	2.84%	-68.74%
ET Energy Transfer LP	22.80%	-9.37%	53.87%	27.87%	55.74%	42.96%	-44.92%	5.88%	-17.74%	-4.66%

Correlation

The correlation between CHRS and ET is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.16
Correlation (10Y) Calculated over the trailing 10-year period	0.18
Correlation (All Time) Calculated using the full available price history since Nov 7, 2014	0.19

The correlation between CHRS and ET shifts across timeframes, from -0.00 (1 year) to 0.19 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CHRS : $207.33M ET : $67.56B
EPS CHRS : $1.52 ET : $1.36
PE Ratio CHRS : 1.00 ET : 14.36
PS Ratio CHRS : 3.96 ET : 0.78
PB Ratio CHRS : 2.64 ET : 1.36
Total Revenue (TTM) CHRS : $46.88M ET : $89.38B
Gross Profit (TTM) CHRS : $23.41M ET : $20.48B
EBITDA (TTM) CHRS : -$162.15M ET : $13.02B

Return for Risk

CHRS vs. ET — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHRS

CHRS Risk / Return Rank: 74
CHRS Sharpe Ratio Rank: 76
CHRS Sortino Ratio Rank: 74
CHRS Omega Ratio Rank: 70
CHRS Calmar Ratio Rank: 77
CHRS Martin Ratio Rank: 72

ET

ET Risk / Return Rank: 73
ET Sharpe Ratio Rank: 77
ET Sortino Ratio Rank: 73
ET Omega Ratio Rank: 67
ET Calmar Ratio Rank: 74
ET Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHRS vs. ET - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and Energy Transfer LP (ET). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CHRS	ET	Difference
Sharpe ratio Return per unit of total volatility	1.22	1.25	-0.03
Sortino ratio Return per unit of downside risk	1.95	1.91	+0.04
Omega ratio Gain probability vs. loss probability	1.23	1.21	+0.02
Calmar ratio Return relative to maximum drawdown	2.32	2.04	+0.28
Martin ratio Return relative to average drawdown	4.28	4.50	-0.22
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CHRS vs. ET - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 1.22, which is comparable to the ET Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of CHRS and ET, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CHRS	ET	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.22	1.25	-0.03
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.41	0.91	-1.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.29	0.36	-0.66
Sharpe Ratio (All Time) Calculated using the full available price history	-0.22	0.36	-0.58

Drawdowns

CHRS vs. ET - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, which is greater than ET's maximum drawdown of -87.81%. Use the drawdown chart below to compare losses from any high point for CHRS and ET.

Drawdown Indicators

	CHRS	ET	Difference
Max Drawdown Largest peak-to-trough decline	-98.21%	-87.81%	-10.40%
Max Drawdown (1Y) Largest decline over 1 year	-41.04%	-10.02%	-31.02%
Max Drawdown (3Y) Largest decline over 3 years	-87.71%	-24.56%	-63.15%
Max Drawdown (5Y) Largest decline over 5 years	-96.47%	-25.82%	-70.65%
Max Drawdown (10Y) Largest decline over 10 years	-97.88%	-72.82%	-25.06%
Current Drawdown Current decline from peak	-95.94%	-4.17%	-91.77%
Average Drawdown Average peak-to-trough decline	-63.47%	-25.75%	-37.72%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.21%	4.54%	+17.67%

Volatility

CHRS vs. ET - Volatility Comparison

Coherus BioSciences, Inc. (CHRS) has a higher volatility of 21.20% compared to Energy Transfer LP (ET) at 6.02%. This indicates that CHRS's price experiences larger fluctuations and is considered to be riskier than ET based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CHRS	ET	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.20%	6.02%	+15.18%
Volatility (6M) Calculated over the trailing 6-month period	60.52%	11.90%	+48.62%
Volatility (1Y) Calculated over the trailing 1-year period	81.10%	16.42%	+64.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.63%	24.90%	+59.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.91%	35.05%	+39.86%

Dividends

CHRS vs. ET - Dividend Comparison

CHRS has not paid dividends to shareholders, while ET's dividend yield for the trailing twelve months is around 6.83%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CHRS Coherus BioSciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ET Energy Transfer LP	6.83%	7.97%	6.51%	8.95%	7.33%	7.41%	17.27%	9.51%	9.24%	6.66%	5.90%	7.42%

Financials

Frequently Asked Questions

Can I hold both CHRS and ET in my portfolio?

CHRS and ET have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CHRS or ET?

CHRS has higher volatility (21.20%) compared to ET (6.02%). In terms of maximum drawdown, CHRS dropped -98.21% vs ET's -87.81%.

Which has better risk-adjusted returns?

ET currently has the higher Sharpe Ratio (1.25 vs 1.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.